MarketBeat
13 May 2026, 03:08 UTC · 26w ago
Verdict
Headline takes no side. We score VRCA +0.90 across five claims — strongly bullish.
+0.90strongly bullish
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
5 claims · scored −1 bearish … +1 bullish
YCANTH U.S. dispensed applicator units surged 51.3% year-over-year and 12.1% sequentially, with record demand continuing to accelerate into April.
More positive than 99% of claims this week
The European Medicines Agency provided positive feedback supporting a Marketing Authorisation Application for YCANTH in molluscum, with no additional phase 3 trials required for approval.
Continue reading
5 related stories
Search tags
More positive than 98% of claims this week
VP-315 demonstrated a 97% objective response rate and an 86% reduction in overall tumor size in phase 2, with market research indicating broad utilization potential among physicians and patients.
More positive than 93% of claims this week
Enrollment in COVE-2, the first phase 3 trial of YCANTH for common warts, has surpassed 50% of its targeted level, with potential to be the first approved therapy for this indication in the U.S. and Japan.
So whatAdvancing the common wart program expands YCANTH's total addressable market to over 22 million people in the U.S., adding significant pipeline value.
More positive than 85% of claims this week
Torii Pharmaceutical launched YCANTH in Japan in February, with commercial supply beginning to offset Verrica's portion of clinical costs for the common wart program.
More positive than 77% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
Reported higher revenue, record demand for YCANTH, and positive progress in phase 3 clinical trials for warts and basal cell carcinoma.
More positive than 78% of ticker scores this week
Successfully launched YCANTH in Japan and is co-funding the common wart program.
More positive than 76% of relationship scores this week
[mutual] Verrica has a license and collaboration partnership with Torii Pharmaceutical for the launch and development of YCANTH.
More positive than 35% of relationship scores this week
[a_to_b] Verrica provides commercial supply of YCANTH to Torii Pharmaceutical for the Japanese market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
1h ago
−48.0%
Price is moving against the score
$3.72 vs $7.15 close before publication (May 12) · not market-adjusted
VRCA chart →
